Table 1.
Patient characteristics in the study
| n | % | ||
|---|---|---|---|
| Age | |||
| 20–29 | 2 | 1.6 | |
| 30–39 | 10 | 8.1 | |
| 40–49 | 29 | 23.6 | |
| 50–59 | 36 | 29.3 | |
| 60–69 | 44 | 35.8 | |
| >70 | 2 | 1.6 | |
| T size (cm) | |||
| ≤1.0 | 2 | 1.6 | |
| 1.1–2.0 | 44 | 35.8 | |
| 2.1–5.0 | 66 | 53.7 | |
| >5.0 | 11 | 8.9 | |
| ER (%) | |||
| − | 18 | 14.6 | |
| + | 105 | 85.4 | |
| PR (%) | |||
| − | 27 | 22.0 | |
| + | 96 | 78.0 | |
| HER‐2 | |||
| − | 92 | 74.8 | |
| + | 30 | 24.4 | |
| Unknown | 1 | 0.8 | |
| PE | |||
| cN0 | 74 | 60.2 | |
| cN1 | 49 | 39.8 | |
| US | |||
| cN0 | 40 | 32.5 | |
| cN1 | 83 | 67.5 | |
| ALN pathology | |||
| pN0 | 40 | 32.5 | |
| pN1 | 83 | 67.5 | |
ALN, axillary lymph node; ER, estrogen receptor; HER‐2, human epidermal growth factor receptor 2; PE, physical examination; PR, progesterone receptor; T, tumour; US, ultrasound.